TABLE 1.
Study Characteristics of Pediatric Cohorts in RLCs and DCs
| Study Authors (Year) | Location | N | Age, Mean (b) or Median (a) | Study Details | Follow-up Time, Total (b) or Median (a), mo |
|---|---|---|---|---|---|
| RLCs | |||||
| Hien et al19 (2009) | Burkina Faso | 52 | 6.8 ya | IAS abstract | 24b |
| Fassinou et al20 (2004) | Cote d'Ivoire | 78 | 7.2 ya | 21% HAART-experienced | 21a |
| Rouet et al21 (2006) | Cote d'Ivoire | 78 | 6.5 ya | PI vs NNRTI comparison | 36a |
| Nyandiko et al22 (2006) | Kenya | 279 | 6.0 ya | Rural, orphan comparison | 34a |
| Song et al23 (2007) | Kenya | 29 | 8.5 yb | Adult comparison | 15b |
| Van Winghem et al24 (2008) | Kenya | 648 | 5.5 ya | Adherence: MSF | 48b |
| Wamalwa et al25 (2007) | Kenya | 67 | 4.4 ya | Early response | 9a |
| Reddi et al26 (2007) | KwaZulu Natal | 151 | 5.7 ya | 16% HAART-experienced | 8a |
| Leyenaar et al27 (2009) | Lesotho | 284 | 2.2 ya | BIPAI center of excellence | 14b |
| Cohen et al28 (2009) | Lesotho | 283 | NR | IAS abstract, rural: MSF | 24b |
| Bong et al29 (2007) | Malawi | 439 | 6.0 ya | FDC | 24b |
| —16 (2006) | Malawi | A: 436 | <15 y | FDC | 6b |
| B: 233 | FDC | 12b | |||
| Weigel et al30 (2010) | Malawi | 497 | 8.0 ya | CROI abstract, growth | 24b |
| Marazzi et al31 (2006) | Mozambique | 297 | 4.4 yb | Integrated public health program | 9a |
| Vaz et al32 (2009) | Mozambique | 1007 | 3.0 ya | IAS abstract, growth | 48b |
| van Griensven et al33 (2008) | Rwanda | 315 | 7.2 ya | Nurse-based care: MSF | 45b |
| Diack MBaye et al34 (2005) | Senegal | 98 | 5.0 ya | Non-specific focus | 36b |
| Barth et al35 (2008) | South Africa | 66 | 8 mo to 11 y | Rural, ART-naive | 12b |
| Eley36 (2006) | South Africa | 409 | 1.9 ya | Severe clinical disease | 12b |
| Jaspan et al37 (2008) | South Africa | 391 | 2.2 ya | PI vs NNRTI comparison | 48b |
| Jooste et al38 (2005) | South Africa | 100 | 1–14 y | Non-specific focus | 6b |
| Smit et al39 (2009) | South Africa | 615 | 1.8 ya | IAS abstract: Cape Town | 46b |
| Blè et al40 (2007) | Tanzania | 59 | 3 mo to 11 y | Orphan study | 12b |
| Kamya et al41 (2007) | Uganda | 250 | 9.2 yb | Genotypic mutations | 14b |
| Bolton-Moore et al42 (2007) | Zambia | 2938 | 6.8 ya | Providers (nonphysicians) | 12a |
| Gupta et al43 (2009) | Zambia | 103 | 8.0 ya | IAS: Triomune FDC | 36b |
| Walker et al44 (2007) | Zambia | 93 | 8.8 ya | Non-specific focus | 24b |
| Janssens et al45 (2007) | Cambodia | 212 | 6.0 ya | Split FDC | 36b |
| Myung et al13 (2007) | Cambodia | 117 | 5.5 ya | DOT | 26b |
| Zhang et al46 (2007) | China | A: 51 | NR | HAART-naive | 13b |
| B: 32 | NR | HAART-experienced | 13b | ||
| Rajasekaran et al47 (2009) | India | 295 | 7.6 yb | Non-specific focus | 10a |
| Kline et al48 (2007) | Romania | 414 | 13.0 yb | 82% drug-experienced | 51a |
| Aurpibul et al49 (2009) | Thailand | 225 | 7.4 ya | IAS: growth | 55b |
| Lapphra et al40 (2008) | Thailand | 139 | 6.0 ya | Siriraj Hospital | 36a |
| Puthanakit et al51 (2007) | Thailand | 192 | 7.6 yb | Chiang Mai Hospitals | 29a |
| Romanelli et al52 (2006) | Brazil | 43 | 2.4 yb | Dual vs triple antiretroviral therapy | 48b |
| Martins et al53 (2009) | Brazil | 196 | NR | IAS: growth | 6b |
| Martins et al54 (2009) | Brazil | 196 | NR | IAS: immunosuppression | 6b |
| George et al12 (2007) | Haiti | 236 | 6.3 ya | Treatment-naive | 20a |
| Severe et al55 (2005) | Haiti | 94 | <13 y | Adult and child study | 12b |
| DCs | |||||
| Ghaffari et al56 (2004) | US | 40 | 7.1 ya | PI: University of Florida, Gainesville | 22b |
| King et al57 (2005) | US | 41 | 6.4 ya | PACTG 403, PI nelfinavir | 11b |
| Krogstad et al58 (1999) | US | 62 | 3 mo to 13 y | PI nelfinavir, age groups | 10a |
| Krogstad et al11 (2002) | US | 192 | 6.2 ya | PACTG 377 | 11b |
| McKinney et al59 (2007) | US | 37 | 10.5 ya | PACTG 1021 | 22b |
| Melvin et al60 (2002) | US | 36 | 6.0 ya | 5 patients overlap PACTG | 29a |
| Patel et al61 (2008) | US | 1236 | NR | PACTG 219 10-y follow-up | 70a |
| Rosenblatt et al62 (2005) | US | 192 | 6.2 ya | PACTG 377 | 11b |
| Soh et al63 (2003) | US | 702 | 6.7 ya | PACTG 219 CD4 response | 48b |
| Spector et al64 (2000) | US | 57 | 8.0 ya | PACTG 382 | 11b |
| Starr et al65 (1999) | US | 57 | 8.0 yb | PACTG 382 | 11b |
| Watson et al66 (1999) | US | 72 | NR | Adherence and efficacy | 9a |
| Wiznia et al67 (2000) | US | 192 | 6.2 ya | PACTG 377 | 11b |
| Yogev et al68 (2002) | US | 245 | 7.4 ya | PACTG 338 subset | 11b |
| Bracher et al69 (2007) | Denmark | 49 | 6.7 ya | Long term follow-up | 72b |
| Teglas et al70 (2001) | France | 33 | 12.5 ya | Efavirenz study | 9b |
| Thuret et al71 (1999) | France | 22 | 6.5 ya | Non-specific focus | 21b |
| Wintergerst et al72 (2008) | Germany | 33 | 8.2 ya | Efavirenz study | 50a |
| Fraaij et al73 (2005) | Netherlands | 31 | 5.1 ya | Prospective PI study | 48b |
| Scherpbier et al74 (2007) | Netherlands | 36 | 6.6 ya | Efavirenz study | 11a |
| van Rossum et al75 (2002) | Netherlands | 32 | 5.4 ya | Non-specific focus | 22b |
| van Rossum et al76 (2000) | Netherlands | 28 | 6.0 ya | Non-specific focus | 6b |
| Verweel et al77 (2002) | Netherlands | 24 | 5.2 ya | HAART effect on growth | 22b |
| Nadal et al78 (2000) | Switzerland | A: 37 | 6.3 ya | Ritonavir | 28a |
| B: 237 | 7.8 ya | Nelfinavir | 28a | ||
| Rudin et al79 (2008) | Switzerland | 133 | 6.3 ya | PI comparison | 66b |
| Judd et al80 (2007) | UK, Ireland | 156 | NR | CHIPS 2003–2006 antiretroviral-naive | >9 |
| Walker et al81 (2004) | UK, Ireland | 265 | 4.2 ya | CHIPS, antiretroviral-naive | 24b |
| PENTA82 (2002) | 8 countries | 103 | 5.3 ya | PENTA | 11b |
IAS indicates International AIDS Society; PI, protease inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; MSF, Medecins Sans Frontiere; BIPAI, Baylor International Pediatric AIDS Initiative; —, No author provided; FDC, fixed-dose combination treatment; CROI, Conference on Retroviruses and Opportunistic Infections; DOT, directly observed therapy; NR, not reported; PACTG, Pediatric AIDS Clinical Trial Group; CHIPS, Collaborative HIV Paediatric Study; PENTA, Paediatric European Network for Treatment of AIDS.
a
Mean/total.
b
Median.